Identification of Single Biomolecules Could Soon Be Even Faster
|
By LabMedica International staff writers Posted on 08 Feb 2016 |
Scientists have developed a breakthrough new method that may soon enable the capture of individual biological molecules 1,000 times faster, leading to more efficient research and diagnostic detection for important medical conditions.
Gathering and identifying molecules for analysis can be done by passing molecules in solution through a nanopore and detecting the change in electric current the molecules create. The problem with this technique, “nanopore sensing,” is that it is usually diffusion-limited, and so relies on molecules drifting close to the nanopore before being captured.
Now, a team led by researchers at Imperial College London (London, UK) in collaboration with colleagues at University of Minnesota (Minneapolis – St. Paul; MN; USA) have demonstrated a technique to attract molecules towards the nanopore, making the process up to 1,000 times more efficient.
“By pulling molecules towards the detector instead of relying purely on diffusion, we can access a much larger volume, and by doing so can detect the same number of molecules from a much smaller concentration,” said senior author Dr. Joshua Edel from Imperial, “What might currently take 5 hours to analyze could be done in a couple of minutes with our new method.”
The technique, “single molecule dielectrophoretic trapping,” will also allow for analysis of very dilute samples. Capability to analyze molecules in low-concentration samples could be particularly important when looking for evidence of epigenetic modifications such as DNA methylation. The team tested their method with DNA molecules, but said it could be modified to detect a wide range of medically important molecules, from proteins to whole cells.
The technique uses an electrically-charged nano-pipette that exerts an electrical attraction force on the molecule that draws it close to the pipette tip, the nanopore. The shape and minute size of the tip, less than 50 nanometres, enables detection of single molecules.
Detecting and analyzing each molecule individually also avoids the problem of averaged results that obscure rare, but possibly important, events. “We can now capture needle-in-a-haystack events,” said coauthors Dr. Aleksandar Ivanov and Dr. Kevin Freedman of Imperial. “The huge increase in efficiency brought about by this technique paves the way for high-speed and high-throughput detection of rare events in ultra-dilute samples.” The team has filed a patent for their invention and expect that it will have application implications in the near future.
The study, by Freedman KJ et al., was published 2016, in the journal Nature Communications.
Related Links:
Imperial College London
University of Minnesota
Gathering and identifying molecules for analysis can be done by passing molecules in solution through a nanopore and detecting the change in electric current the molecules create. The problem with this technique, “nanopore sensing,” is that it is usually diffusion-limited, and so relies on molecules drifting close to the nanopore before being captured.
Now, a team led by researchers at Imperial College London (London, UK) in collaboration with colleagues at University of Minnesota (Minneapolis – St. Paul; MN; USA) have demonstrated a technique to attract molecules towards the nanopore, making the process up to 1,000 times more efficient.
“By pulling molecules towards the detector instead of relying purely on diffusion, we can access a much larger volume, and by doing so can detect the same number of molecules from a much smaller concentration,” said senior author Dr. Joshua Edel from Imperial, “What might currently take 5 hours to analyze could be done in a couple of minutes with our new method.”
The technique, “single molecule dielectrophoretic trapping,” will also allow for analysis of very dilute samples. Capability to analyze molecules in low-concentration samples could be particularly important when looking for evidence of epigenetic modifications such as DNA methylation. The team tested their method with DNA molecules, but said it could be modified to detect a wide range of medically important molecules, from proteins to whole cells.
The technique uses an electrically-charged nano-pipette that exerts an electrical attraction force on the molecule that draws it close to the pipette tip, the nanopore. The shape and minute size of the tip, less than 50 nanometres, enables detection of single molecules.
Detecting and analyzing each molecule individually also avoids the problem of averaged results that obscure rare, but possibly important, events. “We can now capture needle-in-a-haystack events,” said coauthors Dr. Aleksandar Ivanov and Dr. Kevin Freedman of Imperial. “The huge increase in efficiency brought about by this technique paves the way for high-speed and high-throughput detection of rare events in ultra-dilute samples.” The team has filed a patent for their invention and expect that it will have application implications in the near future.
The study, by Freedman KJ et al., was published 2016, in the journal Nature Communications.
Related Links:
Imperial College London
University of Minnesota
Latest Molecular Diagnostics News
- Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
- Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
- Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
- Mesothelioma in Younger Adults Linked to Genetic Risk Factors
- Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
- Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
- Simple Blood Test Enables Multi-Disease Detection from Single Sample
- Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
- Blood-Based ctDNA Test Enhances Risk Assessment in HPV-Related Throat Cancer
- WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
- ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
- Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
- RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
- Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
- New AI Tool Improves Detection of Genetic Causes in Rare Disorders
- Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channelAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







